共查询到20条相似文献,搜索用时 0 毫秒
1.
2.
3.
Anna Aulinas MD PhD Dean A. Marengi BS Francesca Galbiati MD Elisa Asanza NP Meghan Slattery NP Christopher J. Mancuso BS Olivia Wons BS Nadia Micali MD Elana Bern MD Kamryn T. Eddy PhD Jennifer J. Thomas PhD Madhusmita Misra MD Elizabeth A. Lawson MD MMSc 《The International journal of eating disorders》2020,53(4):631-636
4.
5.
6.
7.
Building evidence for the use of descriptive subtypes in youth with avoidant restrictive food intake disorder 下载免费PDF全文
Mark L. Norris MD Wendy Spettigue MD Nicole G. Hammond MA Debra K. Katzman MD Nancy Zucker PhD Katie Yelle MD Alexandre Santos MA Madeline Gray Nicole Obeid PhD 《The International journal of eating disorders》2018,51(2):170-173
8.
P. Evelyna Kambanis BA Megan C. Kuhnle BA Olivia B. Wons BS Jenny H. Jo MA Ani C. Keshishian BA Kristine Hauser FNP Kendra R. Becker PhD Debra L. Franko PhD Madhusmita Misra MD MPH Nadia Micali MD PhD Elizabeth A. Lawson MD MMSc Kamryn T. Eddy PhD Jennifer J. Thomas PhD 《The International journal of eating disorders》2020,53(2):256-265
9.
James Lock MD PhD Shiri Sadeh-Sharvit PhD Alexa L'Insalata BA 《The International journal of eating disorders》2019,52(6):746-751
Treatments for avoidant/restrictive food intake disorder (ARFID) lack strong empirical support. There is a critical need to conduct adequately powered studies to identify effective treatments for ARFID. As a first step, the primary aim of this study was to assess the feasibility of conducting a randomized clinical trial (RCT) comparing Family-based Treatment for ARFID (FBT-ARFID) to usual care (UC). The primary outcomes were recruitment, attrition, suitability, and expectancy rates. The secondary aim was to assess changes in percent estimated body weight, eating related psychopathology, and parental self-efficacy from baseline to end of treatment/UC period in both groups. Recruitment rates were 1.87 per month; 28 children with ARFID and their families were randomized and attrition rate was 21%. Therapeutic suitability and expectancy rating suggested that FBT-ARFID was acceptable to families. Effect size (ES) differences on measures of weight and clinical severity were moderate to large, favoring FBT-ARFID over UC. Parental self-efficacy improvement also demonstrated a large ES favoring FBT-ARFID, which was correlated with improvements in ARFID symptoms. There is a research gap between our knowledge base on how to treat children with ARFID and clinical need. The data presented suggest that an RCT comparing FBT-ARFID and UC is feasible to conduct. 相似文献
10.
11.
Prevalence of DSM‐5 avoidant/restrictive food intake disorder in a pediatric gastroenterology healthcare network 下载免费PDF全文
Kamryn T. Eddy PhD Jennifer J. Thomas PhD Elizabeth Hastings BS Katherine Edkins BA Evan Lamont BA Caitlin M. Nevins BA Rebecca M. Patterson BA Helen B. Murray BA Rachel Bryant‐Waugh PhD Anne E. Becker MD PhD ScM 《The International journal of eating disorders》2015,48(5):464-470
12.
13.
Pudendal nerve entrapment leading to avoidant/restrictive food intake disorder (ARFID): A case report 下载免费PDF全文
Karen Tsai BA Deepan Singh MD Aaron Pinkhasov MD 《The International journal of eating disorders》2017,50(1):84-87
Avoidant/restrictive food intake disorder (ARFID) is a diagnosis in diagnostic and statistical manual of mental disorders‐5 (DSM‐5) manifested by persistent failure to meet nutritional and/or energy needs. Pudendal nerve entrapment (PNE) often causes pelvic discomfort in addition to constipation and painful bowel movements. Current literature on ARFID is sparse and focuses on the pediatric and adolescent population. No association between PNE and ARFID has been described. We present a case of ARFID in an adult male with PNE resulting from subsequent scarring from testicular cancer surgery. The patient's gastrointestinal symptoms due to PNE caused significant food avoidance and restriction subsequently leading to severe malnourishment. Clinicians should be aware that distressing gastrointestinal symptoms arising from a secondary disease process such as PNE might lead to dietary restriction and food aversion. More research is needed for proper screening, detection, and treatment of ARFID. © 2016 Wiley Periodicals, Inc. (Int J Eat Disord 2017; 50:84–87) 相似文献
14.
15.
Alexandra Pennell MD candidate Jennifer Couturier MD Christina Grant MD Natasha Johnson MD 《The International journal of eating disorders》2016,49(11):1036-1039
There is a growing body of literature describing the development, clinical course, and treatment of avoidant/restrictive food intake disorder (ARFID), a diagnostic category introduced in the DSM‐5. However, information surrounding complex cases of ARFID involving coexisting medical and/or psychiatric disorders remains scarce. Here we report on two cases of young patients diagnosed concurrently with ARFID and attention deficit hyperactivity disorder (ADHD) who both experienced significant growth restriction following initiation of stimulant medication. The appetite suppressant effect of stimulants exacerbated longstanding avoidant and restrictive eating behaviors resulting in growth restriction and admission to an inpatient eating disorders unit. The implications of ARFID exacerbated by stimulant‐treated ADHD are explored, as well as the treatment delivered. These cases suggest that further research is needed to explore management options to counteract the appetite suppression effects of stimulants, while simultaneously addressing attention deficit symptoms and oppositional behavior. © 2016 Wiley Periodicals, Inc. (Int J Eat Disord 2016; 49:1036–1039) 相似文献
16.
17.
Jennifer J. Thomas PhD Kendra R. Becker PhD Megan C. Kuhnle BA Jenny H. Jo MA Stephanie G. Harshman PhD Olivia B. Wons BS Ani C. Keshishian BA Kristine Hauser NP Lauren Breithaupt PhD Rachel E. Liebman PhD Madhusmita Misra PhD Sabine Wilhelm PhD Elizabeth A. Lawson MD MMSc Kamryn T. Eddy PhD 《The International journal of eating disorders》2020,53(10):1636-1646
18.
19.
Outcomes of low‐weight patients with avoidant/restrictive food intake disorder and anorexia nervosa at long‐term follow‐up after treatment in a partial hospitalization program for eating disorders 下载免费PDF全文
Amanda E. Bryson MD Anna M. Scipioni BA Jamal H. Essayli PhD Johnna R. Mahoney MD Rollyn M. Ornstein MD 《The International journal of eating disorders》2018,51(5):470-474
20.
Courtney E. Breiner MA McKenzie L. Miller MA Julia M. Hormes PhD 《The International journal of eating disorders》2021,54(12):2229-2235
Evidence-based treatment approaches for avoidant/restrictive food intake disorder (ARFID) remain limited and may be inaccessible to families due to geographic, financial, and/or time constraints. This study aims to establish the acceptability and feasibility of a brief ARFID Parent Training Program (ARFID-PTP), modified from other evidence-based approaches, using a randomized controlled trial design. Participants (n = 30) will be children aged 5–12 who meet diagnostic criteria for ARFID and their parents/guardians. Participants will be randomized to receive treatment immediately or following a 4-week wait (waitlist control). Treatment consists of two, 2-hr virtual treatment sessions with the family and a therapist plus an optional booster session. Primary aims include evaluating the (a) feasibility of ARFID-PTP as indicated by recruitment and retention rates, as well as treatment adherence at home and (b) acceptability as determined by ratings on the Credibility and Expectancy Questionnaire and satisfaction questions. A secondary aim is to assess the preliminary efficacy of ARFID-PTP via changes in scores on the Pica, ARFID, and Rumination Disorder Interview. If results indicate appropriate feasibility and acceptability, the proposed protocol will form the basis for larger scale trials of treatment efficacy in efforts to increase accessibility of evidence-based treatment for ARFID. 相似文献